FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Intracellular topics
Intracellular
Extracellular
Recombinant
Cancer Cells
Side Effects
Cancer Cell
Peptide Sequence
Nanoparticle
Proinflammatory
Dysfunction
Mitochondria
Mitochondrial
Transgenic
Neurotoxic
Pancreatic

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Intracellular patents



      
           
This page is updated frequently with new Intracellular-related patent applications. Subscribe to the Intracellular RSS feed to automatically get the update: related Intracellular RSS feeds. RSS updates for this page: Intracellular RSS RSS


Date/App# patent app List of recent Intracellular-related patents
08/28/14
20140243366
 Compounds that modulate intracellular calcium patent thumbnailnew patent Compounds that modulate intracellular calcium
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (soc) channels. Also described herein are methods of using such soc channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of soc channel activity..
08/28/14
20140243292
 Subsituted 2-(chroman-6-yloxyl)-thiazoles and their use as pharmaceuticals patent thumbnailnew patent Subsituted 2-(chroman-6-yloxyl)-thiazoles and their use as pharmaceuticals
In which ar, r2, r3 and r4 are as defined in the claims. The compounds of the formula i are inhibitors of the sodium-calcium exchanger (ncx), especially of the sodium-calcium exchanger of subtype 1 (ncx1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke.
08/28/14
20140243261
 Method for treating diabetes and fatty liver disese by stimulating cellular metabolism patent thumbnailnew patent Method for treating diabetes and fatty liver disese by stimulating cellular metabolism
The present invention is a method of treating various diseases and conditions through administering a substantial caloric load coupled with administration of hormone to stimulate the body to convert that caloric load and increase metabolism in at least some cells. Body functioning converts intracellular adenosine triphosphate (atp) as a part of normal cell function.
08/28/14
20140242701
 Chimeric antigen receptor patent thumbnailnew patent Chimeric antigen receptor
Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (gitr) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell.. .
08/21/14
20140235790
 Carbohydrate-based compositions and methods for targeted drug delivery patent thumbnailCarbohydrate-based compositions and methods for targeted drug delivery
Provided herein are compositions and methods for intracellular delivery. The compositions are polymer compositions in which the polymer serves as a carrier for therapeutic and/or diagnostic agents.
08/21/14
20140235735
 Protein damage in aging and age-related diseases patent thumbnailProtein damage in aging and age-related diseases
The process of aging and the development of age-related diseases are related to the emerging phenotypes of increasingly damaged and progressively malfunctioning proteomes. The present invention provides methods of preventing aging and age-related diseases in mammals by assessment of protein-specific oxidative damage.
08/21/14
20140235557
 Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine patent thumbnailSmall efficient cell penetrating peptides derived from the scorpion toxin maurocalcine
The invention relates to small cell penetrating peptides (cpp) derived from the scorpion toxin maurocalcine and to their use as vectors for the intracellular delivery of various drugs and agents.. .
08/21/14
20140234868
 Use for glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medical-plant derived ligand patent thumbnailUse for glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medical-plant derived ligand
The present invention relates to glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand acting on lpa1 (lysophosphatidic acid; 1- or 2-acyl-sn-glycerol-3-phosphate), lpa2, lpa3, lpa4 and lpa5 receptors whose efficacy is exhibited physiologically/pharmaceutically via an interaction with subset receptors [lpa1(edg-2), lpa2(edg-4), lpa3(edg-7), lpa4, pla5] in the edg (endothelial differentiation gene) family in g protein-coupled receptors (gpcrs) present in the cell membranes of animals including humans. The gintonin of the present invention can be used to advantage in the prevention and treatment of various diseases arising from reduced calcium concentration and various physiological activities and pharmaceutical activities dependent on calcium, since the gintonin of the present invention interacts with lpa receptors so as to activate a series of signal transmission processes and temporarily induce an increase in free ca2+ in the cytoplasm, and a temporary increase in the intracellular calcium concentration gives rise to a temporary increase in the intracellular calcium concentration in various organs including, inter alia, those of the nervous system, cardiovascular system, endocrine system, reproductive system, digestive system and immune system when the lpa receptors are expressed, with physiological activity being exhibited..
08/21/14
20140234371
 Modified gram positive bacteria and uses thereof patent thumbnailModified gram positive bacteria and uses thereof
The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (lab) or bifidobacterium, with increased stress resistance and/or improved manufacturing, processing and/or storage characteristics. In particular, the invention relates to a gram positive bacterium which accumulate intracellular trehalose.
08/21/14
20140234348
 Universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens patent thumbnailUniversal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
The invention provides compositions and methods for adoptive t cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (univir) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain..
08/21/14
20140234313
Soluble polypeptides
The invention relates generally to polypeptides, such as antibody molecules, that demonstrate high stability and solubility. In particular, the invention relates to polypeptides comprising paired vl and vh domains that demonstrate soluble expression and folding in a reducing or intracellular environment.
08/14/14
20140228516
Bispecific intracellular delivery vehicles
A composition for delivering an agent to a cell, comprising a bispecific affinity reagent and a ph-responsive, membrane destabilizing polymer. The bispecific affinity reagent may include a first affinity reagent covalently linked to a second affinity reagent, wherein the first affinity reagent binds to a molecule on the surface of a cell, and the second affinity reagent binds to an intracellular target..
08/14/14
20140227741
Biological systems for production of highest quality proteins
Vaccines and therapeutic proteins, including polyclonal and monoclonal antibodies, must be maximally pure and stable in their most active native form. This is a requirement for their maximal efficacy, specificity and stability as well as for precluding immune responses against erroneous or damaged moieties.
08/14/14
20140227344
Cell penetrating peptides for intracellular delivery of molecules
The présent invention relates to cell-penetrating peptides characterized in that it comprises an amino acid séquence selected in the group consisting of x1lx2ralwx9lx3x9x4lwx9lx5x6x7x8, x1lx2larwx9lx3x9x4lwx9lx5x6x7x8 and x1lx2arlwx9lx3x9x4lwx9lx5x6x7x8, wherein x1 is beta-a or s, x2 is f or w, x3 is l, w, c or i, x4 is s, a, n or t, xs is l or w, x6 is w or r, x7 is k or r, x8 is a or none, and x9 is r or s. Thèse peptides exhibit high efficiency, low toxicity and a natural tropism for lung tissues, and can be used either in simple complex with the cargo to be vectorised, or in nanoparticles comprising two layers of cell-pentrating peptides around the cargo..
08/14/14
20140227262
Pd-1 antagonists and methods for treating infectious disease
Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by binding to and blocking pd-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of pd-1 such as pd-l1, thereby preventing (in whole or in part) the ligand from binding to pd-1 to deliver an inhibitory signal.
08/14/14
20140227229
Modified gram positive bacteria and uses thereof
The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose.
08/14/14
20140227185
Glutathione-based drug delivery system
The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like dna vaccines, antisense oligonucleotides, ribozymes, catalytic dna (dnazymes) or rna molecules, sirnas or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (cns), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs.
08/07/14
20140222123
Nanopillar electrode devices and methods of recording action potentials
This disclosure provide a nanopillar electrode device, comprising a substrate patterned with a plurality of metal pads. The device may further comprise a plurality of nanopillars electrode arrays, wherein each nanopillar electrode array is attached to the substrate above a metal pad and electrically connected to the pad.
08/07/14
20140220039
Apoiii and the treatment and diagnosis of diabetes
The present invention provides methods of identifying candidate compounds for the treatment of type i diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein ciii (“apociii”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apociii-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type i diabetes comprising administering to the patient an amount effective of an inhibitor of apociii to reduce apociii-induced increase in intracellular calcium concentration in pancreatic β cells..
08/07/14
20140219976
Methods and compositions for treatment of retinal degeneration
Disclosed herein are methods and compositions for treating glaucoma, using descendents of marrow adherent stem cells that have been engineered to express an exogenous notch intracellular domain.. .
08/07/14
20140219956
Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
07/31/14
20140213775
Intracellular cell selection
The disclosure relates to a magnetic particle comprising: a ligand that specifically binds an intracellular antigen, a cell membrane penetrating cationic peptide and a peptide comprising an amino acid sequence that is adapted to interact with the secretory pathway in a cell and the use of the particle in selection of cells from heterogeneous cell populations.. .
07/31/14
20140213559
Compositions and treatments for dystrophies
The present invention provides an inhibitor of intracellular protein degradation for use in the treatment and prevention of muscular dystrophy in a mammal. In particular, the invention provides an autophagy inhibitor and/or an inhibitor of the ubiquitin-proteasome system (such as a proteasome inhibitor) for use in the treatment and prevention of muscular dystrophy (such as congenital muscular dystrophy [e.g.
07/31/14
20140212455
Recombinant bcg strains with enhanced ability to inhibit intracellular mycobacterial growth
A recombinant bacterial cell strain is disclosed. It comprises: a) a first vector comprising a fusion transgene encoding ag85b-cfp10 fusion protein, the fusion transgene being operably linked to a promoter effective for expression of the ag85b-cfp10 fusion protein; and b) a second vector comprising a transgene encoding interleukin-12 (il-12), the transgene being operably linked to a promoter effective for expression of the il-12 protein.
07/24/14
20140206596
Design of ph-sensitive oligopeptide complexes for drug release under mildly acidic conditions
The present invention discloses a design for a molecular delivery vehicle capable of delivering a molecular payload to a target cell and its intracellular compartments. Also disclosed are highly ph-sensitive nanoconstruct that takes advantage of the requirement of cationic charge for internalization of cpps to mask the non-specific internalization, compositions containing nanoconstruct, and methods for forming the same..
07/24/14
20140206081
Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
The present invention relates to the use of variable domains of camelid heavy-chain antibodies (vhh domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns vhh domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents..
07/24/14
20140205660
Abscisic acid against cancer
Abscisic acid (aba) a naturally occurring plant hormone has been identified in this invention with potent properties to fight cancer. Aba is able to produce a hyperpolarization condition on plasma membrane through a decrease of intracellular na+ and k+.
07/24/14
20140205656
Modified cationic liposome adjuvants
The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the igg sub-type response and enhancing the cd8 response of the liposomal adjuvant. This technology can be used to increase the production of igg2 antibodies.
07/17/14
20140200319
Fluorescent potassium ion sensors
This disclosure relates generally to potassium ion sensors and monomers derived from such sensors. The disclosure also provides for polymers (e.g., random copolymers, nanoparticles, polymer thin films, and sensors) having polymerized monomeric potassium ion sensors as described herein.
07/17/14
20140199330
Protein involved in detection of cancer metastasis and a treatment thereof
Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is trpv4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma in situ, a pre-neoplastic lesion and normal tissues.
07/10/14
20140194325
Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
The present invention provides compositions and methods for detection and analysis of intracellular binding of a bioactive agent to a cellular target. In particular, provided herein are bioactive agents tethered to fluorophores, cellular targets fused to bioluminescent reporters, and methods of detecting and analyzing the interaction of bioactive agents with cellular targets therewith..
07/10/14
20140194307
Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
The present invention provides compositions and methods for detection and analysis of intracellular binding of a bioactive agent to a cellular target. In particular, provided herein are bioactive agents tethered to fluorophores, cellular targets fused to bioluminescent reporters, or portions, components, or subunits of bioluminescent reporters, and methods of detecting and analyzing the interaction of bioactive agents with cellular targets therewith..
07/10/14
20140190367
Galactose-rich polysaccharide, process for the production of the polymer and its applications
This invention concerns a biopolymer consisting of a polysaccharide composed of galactose (50-90%), glucose (1-25%), mannose (1-25%) and rhamnose (0.5-20%), which may additionally contain, in trace amounts, xylose, fucose, ribose, arabinose and/or fructose. The galactose-rich polymer also contains non-saccharide components, namely, acyl groups.
07/03/14
20140186900
Production of fungal extracellular immune stimulating compounds
A process is described for the production of an immunostimulant by submerged cultivation of ganoderma lucidum in which mycelium from agar plates or a fermentation broth is added to a liquid medium in a shake flask or a bioreactor containing nutrients such as malt extract, yeast extract, peptone and glucose having access to air or to which air is added, and which is kept in constant movement at approx. 28° c.
07/03/14
20140186364
Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (nt-3 or nt3), to the extracellular domain or trkc receptor and/or to inhibit the dimerization of the intracellular domain of the trkc receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3.
07/03/14
20140186328
Neuroprotective polyphenol analogs
The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration.
07/03/14
20140186316
Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
Disclosed herein are methods for the treatment of traumatic brain injury by transplantation of cells descended from marrow adherent stem cells that express an exogenous notch intracellular domain. The transplanted cells form a pathway along which endogenous neurogenic cells proliferate and migrate from the subventricular zone to the site of injury..
06/26/14
20140179901
Peptide conjugates and fluorescence detection methods for intracellular caspase assay
Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and quantitated by the changes in fluorescence.
06/26/14
20140179543
Identification of small-molecule candidate therapeutics capable of inhibiting or interfering with a target protein-protein interaction
The present invention provides a method of screening method small-molecule candidate therapeutics capable of inhibiting or interfering with intracellular protein-protein interactions, such as cancer associated oncogenic protein interactions and in particular ras and lmo2 protein-protein interactions. The present invention also provides methods and assays for rationalized drug design based on identifying small molecular weight protein-protein interaction inhibitor molecules that emulate antibody therapeutics products..
06/26/14
20140178560
Method for the production of powdered olive
The subject of this invention is the production process of whole olive powder with easily pourable properties and natural olive powder that is produced with this processes. Olive and olive oil are used by human beings with different receipts and forms of utilization for more than thousands years.
06/19/14
20140171376
Light-sensitive chimeric gpcr protein
A light-sensitive chimeric protein comprising domains from at least two members of the g-protein-coupled-receptor (gpcr) protein super family, which are fused to yield a light-sensitive gpcr chimera capable of coupling a light signal to the signaling cascade of the metabotropic glutamate receptor 6 (mglur6) is provided for medical therapy and for the manufacture of medicaments for improving vision, in particular for treating loss of vision resulting from retinal photoreceptor degeneration. A first of the at least two gpcr family members contributes domains which mediate the light-sensitivity to the chimeric light-sensitive gpcr protein.
06/19/14
20140170175
Novel lipids and compositions for intracellular delivery of biologically active compounds
The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery..
06/12/14
20140163042
Enzyme inhibitors
Compounds of formula (i) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein r1 is a carboxylic acid group (—cooh), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; r2 is the side chain of a natural or non-natural alpha amino acid; y is a bond, —c(═o), —s(═o)2—, —c(═o)o—, —c(o)nr3—, —c(═s)—nr3, —c(═nh)nr3 or —s(═o)2nr3— wherein r3 is hydrogen or optionally substituted c1-c6 alkyl; l1 is a divalent radical of formula -(alk1)m(q)n(alk2)p- wherein m, n and p are independently 0 or 1, q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —x2-q1- or -q1-x2— wherein x2 is —o—, s— or nra— wherein ra is hydrogen or optionally substituted c1-c3 alkyl, and q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, alk1 and alk2 independently represent optionally substituted divalent c3-c7 cycloalkyl radicals, or optionally substituted straight or branched, c1-c6 alkylene, c2-c6 alkenylene, or c2-c6 alkynylene radicals which may optionally contain or terminate in an ether (—o—), thioether (—s—) or amino (—nra—) link wherein ra is hydrogen or optionally substituted c1-c3 alkyl; x1 represents a bond; —c(═o); or —s(═o)2—; —nr4c(═o)—, —c(═o)nr4—, —nr4c(═o)nr5—, —nr4s(═o)2—, or —s(═o)2nr4— wherein r4 and r5 are independently hydrogen or optionally substituted c1-c6 alkyl; z is 0 or 1; a represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals r1r2nh—y-l1-x1-[ch2]z— and honhco-[linker]- are attached different ring atoms; and -[linker]- represents a divalent linker radical linking a ring atom in a with the hydroxamic acid group coniioii, the length of the linker radical, from the terminal atom linked to the ring atom of a to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.. .
06/12/14
20140163034
Inhibitors of anandamide transport and their therapeutic uses
Nucleic acid and polypeptide sequences corresponding to flat, a partly cytosolic variant of the intracellular anandamide-degrading enzyme, fatty acid amide hydrolase-1 (faah-1), are provided. Flat lacks amidase activity but binds the endocannibinoid anandamide and facilitates its transport into cells.
06/12/14
20140162962
Novel lipids and compositions for intracellular delivery of biologically active compounds
The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery..
06/12/14
20140162934
Novel lipids and compositions for intracellular delivery of biologically active compounds
The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery..
06/12/14
20140161893
Polymer blend particles for intracellular delivery of agents
Core-shell polymer blend particles are described. The particles include a ph-responsive polymeric shell and a ph-irresponsive polymeric core.
06/05/14
20140155439
Enzyme inhibitors
Compounds of formula (i), inhibit hdac activity: wherein a, b and d independently represent ═ch— or ═n—; w is —ch═ch— or —ch2ch2—; r1 is a carboxylic acid group (—cooh), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; r2 and r3 are selected from the side chains of a natural or non-natural alpha amino acid, provided that neither r2 nor r3 is hydrogen, or r2 and r3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; y is a bond, —c(c═o)—, —s(═o)2—, —c(c═o)o—, —c(c═o)nr′—, —c(═s)—nr′, —c(═nh)nr′ or —s(═o)2nr— wherein r′ is hydrogen or optionally substituted c1-c6 alkyl; l1 is a divalent radical of formula -(alk1)m(q)(alk2)p— wherein in, n, p, q, aik1 and aik2 are as defined in the claims; x1 represents a bond; —c(═o); or —s(═o)2—; —nr4c(═o)—, —c(c═o)nr4—, —nr4c(═o)nr5—, —nr4s(═o)2—, or —s(═o)2nr4— wherein r4 and r5 are independently hydrogen or optionally substituted c1-c6 alkyl; and z is 0 or 1.. .
06/05/14
20140155285
Novel cell line screening method
The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by facs or macs.
05/29/14
20140147861
Markers to identify primary cells from tumor biopsies
A process that utilizes a panel of primary monoclonal antibodies (mabs) specific for cell markers that are directly conjugated to fluorophores (alexa fluor dyes and quantum dots). The mab-fluorophore conjugates are used to interrogate the presence or absence and relative level of expression of each of the cell markers using laser scanning confocal microscopy.
05/29/14
20140147860
Acoustic cytometry methods and protocols
Various embodiments disclosed herein comprise acoustic cytometry based methods, kits, computer software methods and systems to analyze a variety of bioparticles. In one embodiment, a method for analyzing bioparticles comprises: acoustically focusing one or more bioparticles through an interrogation zone; optically exciting the one or more bioparticles in the interrogation zone with an excitation source; detecting an optical signal from the bioparticles; and analyzing the optical signal to characterize at least one quality or quantity parameter of the bioparticles.
05/29/14
20140147414
Compositions and methods for treatment of intracellular damage
Pre-implantation factor (pif) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering pif to a subject in need thereof.
05/22/14
20140142492
Electro-microneedle integrated body for in-situ cutaneous gene transfer and method of manufacturing same
Provided is an electro-microneedle integrated body in which a dissolving microneedle and an electrode for electroporation are integrated into one, which enables a focused and efficient intracutaneous gene release for percutaneous gene delivery and intracellular gene delivery occurring in one in-situ treatment site the electro-microneedle integrated body according to the present invention includes an electrode for electroporation which is contacted with skin of a human body to apply an electric field pulse, including a base part and a plurality of electrode parts protruding from the base part, and a microneedle adhered to each electrode part and inserted into the skin of a human body, including a biocompatible and biodegradable viscous material and a genetic material, wherein the microneedle degrades within the skin, and the electric field pulse is applied through the electrode for electroporation in a site in which the microneedle is inserted.. .
05/22/14
20140142286
Cell culture process
A method for producing recombinant polypeptides, including antibodies, having targeted levels of carboxyl terminal (c-terminal) lysine or arginine residues is presented. The method involves culturing cells expressing said polypeptides in cell culture medium having sufficient levels of lysine, arginine, and/or agents that change intracellular ph.
05/22/14
20140140998
Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
Disclosed herein are methods to inhibit cleavage of a type i receptor of transforming growth factor beta (tβri) and reduce cancer cell invasiveness/metastasis, and agents and pharmaceutical compositions for use in these methods. Also disclosed herein are methods for identifying agents that inhibit cleavage of tβri and methods for diagnosing and/or prognosing cancer based on nuclear localization of a intracellular domain of tβri, which is a product of tβri cleavage..
05/22/14
20140140929
Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds
The present invention relates to a system for intracellular delivery of a cargo comprising at least one component a chosen from aliphatic linear or branched moieties with at least 4 carbon atoms and/or cyclic ring systems comprising 2-4 rings which may contain several hetero atoms chosen from n, s, o and p, wherein component(s) a is (are) attached to a cell penetrating peptide b and/or a non-peptide analogue thereof. It also relates to methods of using the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition a material covered with the system and a material having the delivery systems into the material.
05/15/14
20140135381
Small molecule conjugates for intracellular delivery of biologically active compounds
The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized sirna particular useful when covalently attached to a delivery polymer to achieve in vivo mrna knock down are disclosed therein..
05/15/14
20140135380
Small molecule conjugates for intracellular delivery of nucleic acids
The invention provides use of novel compounds for delivery of nucleic acids, and conjugates of these compounds with nucleic acids. Further novel design criteria for chemically stabilized sirna particular useful when covalently attached to said compounds and co-administered with a delivery polymer to achieve mrna knock down in vivo are disclosed therein..
05/15/14
20140134730
Method for inhibiting cell proliferation by oxidative stress
Further, the present invention relates to a method for promoting intracellular oxidative stress, comprising administration of a monoclonal antibody having an inhibitory activity of intracellular uptake of neutral amino acids or an antibody fragment thereof. Also, the present invention relates to a method for inhibiting cell proliferation, comprising administration of a monoclonal antibody having an inhibitory activity of intracellular uptake of neutral amino acids or an antibody fragment thereof and promotion of intracellular oxidative stress..
05/15/14
20140134682
Processes and recombinant microorganisms for the production of cadaverine
Recombinant microorganisms comprising dna molecules in a deregulated form which improve the production of cadaverine or n-acetylcadaverine, as well as recombinant dna molecules and polypeptides used to produce the microorganisms are provided. Said microorganisms comprise an intracellular lysine decarboxylase activity and a deregulated cadaverine export activity, or comprise a decreased cadaverine export activity and an enhanced n-acetylcadaverine forming activity.
05/15/14
20140134192
Methods and compositions for wound treatment
The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.. .
05/08/14
20140128800
Photoactivatable receptors and their uses
Provided herein is a chimeric photoactivatable polypeptide comprising an opsin membrane receptor, wherein an intracellular domain of the opsin membrane receptor is replaced with a corresponding intracellular domain of a chemokine receptor, a sphingosine-1-phosphate receptor or an atp receptor and uses thereof. Further provided are methods of treating cancer, injury of the nervous system, autoimmune disease, and graft rejection comprising administering to the subject a cell that expresses the chimeric photoactivatable polypeptide and exposing the cell to a visible light source..
05/08/14
20140128635
Transformant for production of lactic acid of high optical purity and method for producing lactic acid using the same
Disclosed is the biological production of lactic acid using a microorganism. A transformant capable of producing lactic acid of high optical purity at high yield, a method for the preparation thereof, and a method for producing lactic acid in a convenient and economically beneficial manner using the same are provided.
05/01/14
20140121587
Injection needle and device
Several needle assemblies and intracellular delivery devices that are used for the delivery of prophylactic and/or therapeutic material (i.e., delivered agents) into a tissue of a subject are disclosed. Preferably, the needle assemblies and/or the intracellular delivery devices comprise needles and/or needle electrodes, which are disposed in an array (e.g., a y-type array having three outer needles and a center needle), wherein each needle in the array has a closed end and a plurality of apertures along each needle barrel, and the apertures on the needle barrels of the outer needles of the array are positioned to deliver the delivered agent toward the apertures of the center needle and/or an adjacent needle, but not outside of the active zone defined by the area within the needle array and the apertures on the needle barrel of the center needle are positioned to deliver the delivered agent toward the outer needles..
05/01/14
20140121273
Method for treatment of magnesium and potassium deficiencies
A method for the treatment of depleted intracellular and serum magnesium levels by administration of a highly bioavailable magnesium salt is disclosed. A prescription dispensing system is also disclosed.
05/01/14
20140121169
Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cgmp.
05/01/14
20140120167
Multifunctional chemo- and mechanical therapeutics
Methods of treating diseases through the intracellular enhancement and synergy of chemo- and radiation-therapies by employing cancer cell-specific on-demand mechanical intracellular impact. The methods, quadrapeutics, combines four clinically validated modalities: encapsulated drugs, colloidal gold nanoparticles (gnps), near-infrared short laser pulses, and x-rays..
04/24/14
20140113005
Compounds useful as inhibitors of atr kinase
Wherein l, n, r1, and r2 are as described in the specification. These compounds are useful as inhibitors of atr protein kinase.
04/17/14
20140106341
Stabilized bioactive peptides and methods of identification, synthesis, and use
An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon.
04/10/14
20140100283
Method to increase absorption and bioavailability of oral glutathione
An improved method for delivery of glutathione, a major intracellular antioxidant, by oral administration of s-acetyl-glutathione (sag) is provided. The method is designed to raise the circulating blood levels of glutathione via the administration of an effective amount of sag in a delayed release composition..
04/10/14
20140100265
Gene delivery vehicles in the treatment of neurodegenerative diseases
Currently no therapies that provide either protection or restoration of neuronal function for adult onset neurodegenerative diseases such as parkinson's disease exist. Many clinical efforts to provide such benefits by infusion of neurotropic factors have failed.
04/10/14
20140100130
Methods and compositions for the diagnosis of ovarian cancer
A diagnostic reagent or device comprises at least one ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (clic4) or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. An alternative diagnostic reagent or device comprises ligand or ligands capable of specifically complexing with, binding to, or quantitatively detecting or identifying multiple tropomyosin biomarkers.


Popular terms: [SEARCH]

Intracellular topics: Intracellular, Extracellular, Recombinant, Cancer Cells, Side Effects, Cancer Cell, Peptide Sequence, Nanoparticle, Proinflammatory, Dysfunction, Mitochondria, Mitochondrial, Transgenic, Neurotoxic, Pancreatic

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Intracellular for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Intracellular with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.5214

3525

1 - 1 - 72